


## Octimibate

## Chemical Properties

CAS No. : 89838-96-0  
Formula: C<sub>29</sub>H<sub>30</sub>N<sub>2</sub>O<sub>3</sub>  
Molecular Weight: 454.56  
Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year  
Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Octimibate (Octimibato) is a non-prostaglandin platelet aggregation inhibitor and cyclic prostaglandin agonist. Octimibate is used in the treatment of cardiovascular disease and can be used to study atherosclerosis and thrombosis.
Targets(IC50)	Others, Prostaglandin Receptor
In vitro	<p>In suspensions of washed (plasma-free) human platelets, octimibate is a potent inhibitor of aggregation; its IC<sub>50</sub> is approx 10 nM for inhibition of aggregation is stimulated by several different agonists, including U46619 and ADP. The inhibitory effects of octimibate on aggregation are not competitive with the stimulatory agonist; the maximal response is suppressed but there is no obvious shift in potency of the agonist. In platelet-rich plasma, octimibate inhibits agonist-stimulated aggregation with an IC<sub>50</sub> of approx 200 nM.[2]</p> <p>Octimibate increases cyclic AMP concentrations in platelets and increases the cyclic AMP-dependent protein kinase activity ratio. Octimibate stimulates adenylyl cyclase activity in human platelet membranes, with an EC<sub>50</sub> of 200 nM. The maximal achievable activation of adenylyl cyclase by octimibate is 60% of that obtainable with iloprost. Octimibate has no effect on the cyclic GMP-inhibited phosphodiesterase (phosphodiesterase-IT1), which is the major cyclic AMP-degrading enzyme in human platelets.[2]</p>

## Solubility Information

Solubility	DMSO: 50 mg/mL (110 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	2.1999 mL	10.9996 mL	21.9993 mL
5 mM	0.440 mL	2.1999 mL	4.3999 mL
10 mM	0.220 mL	1.100 mL	2.1999 mL
50 mM	0.044 mL	0.220 mL	0.440 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Merritt JE, et al. Primate vascular responses to octimibate, a non-prostanoid agonist at the prostacyclin receptor. *Br J Pharmacol.* 1991;102(1):260-266.

Merritt JE, et al. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor. *Br J Pharmacol.* 1991;102(1):251-259.

Seiler S, et al. Octimibate inhibition of platelet aggregation: stimulation of adenylate cyclase through prostacyclin receptor activation. *J Pharmacol Exp Ther.* 1990;255(3):1021-1026.

Kowala MC, et al. Prostacyclin agonists reduce early atherosclerosis in hyperlipidemic hamsters. Octimibate and BMY 42393 suppress monocyte chemotaxis, macrophage cholesteryl ester accumulation, scavenger receptor activity, and tumor necrosis factor production. *Arterioscler Thromb.* 1993;13(3):435-44

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481